INS and pancreatic insulinoma: Using the INS-1 rat insulinoma cell line, Kemp et al.[52] were among the first to prove that melatonin is a short-term inhibitory agent modulating glucagon-like peptide 1 (GLP1)-stimulated insulin secretion from pancreatic β-cells.